Drug Search Results
More Filters [+]

Telcagepant

Alternative Names: telcagepant, mk-0974, mk0974
Latest Update: 2024-01-01
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: CGRP Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Merck
Company Location: KENILWORTH NJ 07033
Company CEO: Robert M. Davis
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Telcagepant

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Migraine Disorders|Coronary Artery Disease|Peripheral Vascular Diseases|Cerebrovascular Disorders|Ischemic Attack, Transient|Peripheral Arterial Disease|Ischemic Stroke

Phase 2: Migraine Disorders

Phase 1: Angina, Stable|Migraine Disorders|Coronary Artery Disease|Angina Pectoris|Myocardial Ischemia

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

MK-0974-067

P1

Completed

Migraine Disorders

2011-07-26

MK0974-065

P3

Completed

Migraine Disorders

2011-04-08

MK-0974-065

P3

Completed

Migraine Disorders

2011-04-08

MK-0974-034

P3

Completed

Ischemic Attack, Transient|Peripheral Vascular Diseases|Migraine Disorders|Cerebrovascular Disorders|Peripheral Arterial Disease|Ischemic Stroke

2009-09-02

Recent News Events